Developing a set of indicators to monitor the performance of the pharmaceutical industry:
The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitat...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2023
|
| Schriftenreihe: | OECD Health Working Papers
|
| Schlagworte: | |
| Online-Zugang: | kostenfrei |
| Zusammenfassung: | The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework |
| Beschreibung: | 1 Online-Ressource (75 Seiten) 21 x 28cm |
| DOI: | 10.1787/3b5ca61c-en |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV050074459 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 241209s2023 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/3b5ca61c-en |2 doi | |
| 035 | |a (ZDB-13-SOC)098549758 | ||
| 035 | |a (OCoLC)1492107291 | ||
| 035 | |a (DE-599)BVBBV050074459 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Keelara, Rishub |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Developing a set of indicators to monitor the performance of the pharmaceutical industry |c Rishub, Keelara ... [et al] |
| 264 | 1 | |a Paris |b OECD Publishing |c 2023 | |
| 300 | |a 1 Online-Ressource (75 Seiten) |c 21 x 28cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers | |
| 520 | |a The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Wenzl, Martin |4 ctb | |
| 700 | 1 | |a Waagstein, Lisbeth |4 ctb | |
| 700 | 1 | |a Moens, Marjolijn |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/3b5ca61c-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-035411821 | |
Datensatz im Suchindex
| _version_ | 1823668287531122688 |
|---|---|
| adam_text | |
| any_adam_object | |
| author | Keelara, Rishub |
| author2 | Wenzl, Martin Waagstein, Lisbeth Moens, Marjolijn |
| author2_role | ctb ctb ctb |
| author2_variant | m w mw l w lw m m mm |
| author_facet | Keelara, Rishub Wenzl, Martin Waagstein, Lisbeth Moens, Marjolijn |
| author_role | aut |
| author_sort | Keelara, Rishub |
| author_variant | r k rk |
| building | Verbundindex |
| bvnumber | BV050074459 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)098549758 (OCoLC)1492107291 (DE-599)BVBBV050074459 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/3b5ca61c-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV050074459</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">241209s2023 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/3b5ca61c-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)098549758</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1492107291</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV050074459</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Keelara, Rishub</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Developing a set of indicators to monitor the performance of the pharmaceutical industry</subfield><subfield code="c">Rishub, Keelara ... [et al]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (75 Seiten)</subfield><subfield code="c">21 x 28cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wenzl, Martin</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waagstein, Lisbeth</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moens, Marjolijn</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/3b5ca61c-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-035411821</subfield></datafield></record></collection> |
| id | DE-604.BV050074459 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-10T11:06:47Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-035411821 |
| oclc_num | 1492107291 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (75 Seiten) 21 x 28cm |
| psigel | ZDB-13-SOC |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Keelara, Rishub Verfasser aut Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] Paris OECD Publishing 2023 1 Online-Ressource (75 Seiten) 21 x 28cm txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework Social Issues/Migration/Health Wenzl, Martin ctb Waagstein, Lisbeth ctb Moens, Marjolijn ctb https://doi.org/10.1787/3b5ca61c-en Verlag kostenfrei Volltext |
| spellingShingle | Keelara, Rishub Developing a set of indicators to monitor the performance of the pharmaceutical industry Social Issues/Migration/Health |
| title | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_auth | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_exact_search | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_full | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_fullStr | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_full_unstemmed | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_short | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_sort | developing a set of indicators to monitor the performance of the pharmaceutical industry |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/3b5ca61c-en |
| work_keys_str_mv | AT keelararishub developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT wenzlmartin developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT waagsteinlisbeth developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT moensmarjolijn developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry |